Matches in Nanopublications for { ?s ?p "[Overexpression of CYR61, CTGF, WISP-1, and NOV occurred in 48% (32 of 66), 58% (38 of 66), 36% (24 of 66), and 15% (10 of 66) of primary gliomas, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- NP242183.RAgunNlF4h45nc79epzlBMGTMVFOou1UmsMVWgSuUYP5c130_assertion description "[Overexpression of CYR61, CTGF, WISP-1, and NOV occurred in 48% (32 of 66), 58% (38 of 66), 36% (24 of 66), and 15% (10 of 66) of primary gliomas, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP242183.RAgunNlF4h45nc79epzlBMGTMVFOou1UmsMVWgSuUYP5c130_provenance.
- NP632359.RA0kxNcL_azBs_E2nDijK-RSgWvHIhWWs5NTcc36Fa82w130_assertion description "[Overexpression of CYR61, CTGF, WISP-1, and NOV occurred in 48% (32 of 66), 58% (38 of 66), 36% (24 of 66), and 15% (10 of 66) of primary gliomas, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP632359.RA0kxNcL_azBs_E2nDijK-RSgWvHIhWWs5NTcc36Fa82w130_provenance.
- NP675134.RA3YDceQjb7d4_4ikgh6BnYCx-rZWTUuoUeSeKBi7C8wU130_assertion description "[Overexpression of CYR61, CTGF, WISP-1, and NOV occurred in 48% (32 of 66), 58% (38 of 66), 36% (24 of 66), and 15% (10 of 66) of primary gliomas, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP675134.RA3YDceQjb7d4_4ikgh6BnYCx-rZWTUuoUeSeKBi7C8wU130_provenance.
- NP436965.RA6eyDxJSkjAChEUI71n8TFeRzGxYxUl1JvbJcFMET_-I130_assertion description "[Overexpression of CYR61, CTGF, WISP-1, and NOV occurred in 48% (32 of 66), 58% (38 of 66), 36% (24 of 66), and 15% (10 of 66) of primary gliomas, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP436965.RA6eyDxJSkjAChEUI71n8TFeRzGxYxUl1JvbJcFMET_-I130_provenance.
- NP436967.RA0v2fzWwIM3YfZH7pqNNaELJVKeeXMwmp1eZIEu_lUqA130_assertion description "[Overexpression of CYR61, CTGF, WISP-1, and NOV occurred in 48% (32 of 66), 58% (38 of 66), 36% (24 of 66), and 15% (10 of 66) of primary gliomas, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP436967.RA0v2fzWwIM3YfZH7pqNNaELJVKeeXMwmp1eZIEu_lUqA130_provenance.
- assertion description "[Overexpression of CYR61, CTGF, WISP-1, and NOV occurred in 48% (32 of 66), 58% (38 of 66), 36% (24 of 66), and 15% (10 of 66) of primary gliomas, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP631622.RAtG6VtNQ0oRX-moSCztf2s26F5AfjJul-5jGNy-K8VA8130_assertion description "[Overexpression of CYR61, CTGF, WISP-1, and NOV occurred in 48% (32 of 66), 58% (38 of 66), 36% (24 of 66), and 15% (10 of 66) of primary gliomas, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP631622.RAtG6VtNQ0oRX-moSCztf2s26F5AfjJul-5jGNy-K8VA8130_provenance.
- NP596767.RApVsmNnjT1nnOREfqrvCFv9kUUK60lv25dZLZK6_yHy0130_assertion description "[Overexpression of CYR61, CTGF, WISP-1, and NOV occurred in 48% (32 of 66), 58% (38 of 66), 36% (24 of 66), and 15% (10 of 66) of primary gliomas, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP596767.RApVsmNnjT1nnOREfqrvCFv9kUUK60lv25dZLZK6_yHy0130_provenance.
- NP436968.RAhnsuUhugu7g8zpK-JgI--aKoBgUXzST-A3Za4darXXU130_assertion description "[Overexpression of CYR61, CTGF, WISP-1, and NOV occurred in 48% (32 of 66), 58% (38 of 66), 36% (24 of 66), and 15% (10 of 66) of primary gliomas, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP436968.RAhnsuUhugu7g8zpK-JgI--aKoBgUXzST-A3Za4darXXU130_provenance.